Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476387 | 0.93 | IDO1 (0.47) | IDO1TDO2ALDH1A1SLC18A3SIGMAR1 | |
| SCHEMBL241692 | 0.93 | IDO1 (0.47) | IDO1TDO2ALDH1A1SLC18A3SIGMAR1 | |
| SCHEMBL6480579 | 0.84 | SMN1; SMN2 (0.45) | IDO1TDO2SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10673316 | 0.84 | CYP3A4 (0.43) | IDO1TDO2TDP1CTSL | |
| SCHEMBL8806183 | 0.84 | ALDH1A1 (0.47) | IDO1TDO2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5090023 | 0.84 | SRD5A2 (0.53) | IDO1TDO2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL30598700 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1L3MBTL1CTSL | |
| SCHEMBL3346119 | 0.82 | ACP3 (0.42) | IDO1TDO2MEN1KMT2A | |
| SCHEMBL28483704 | 0.80 | IDO1 (0.42) | IDO1TDO2ALDH1A1SLC18A3SIGMAR1 | |
| SCHEMBL2185727 | 0.80 | ALDH1A1 (0.46) | IDO1TDO2ALDH1A1SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | COGMOTIV FLEXCO (AT) | 2026-04-28 | — | — | US | disclosed |
| US-20220324821-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES | COGMOTIV FLEXCO (AT) | 2022-10-13 | — | — | US | disclosed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| CN-114401948-A | Thiazole and diphenyl substituted sulfoxides for improving cognitive function and combating substance addiction | 红牛有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021259798-A1 | ((((3-HALOPHENYL)(PHENYL)METHYL)SULFINYL)METHYL)THIOPHENE COMPOUNDS AND DIASTEREOMERIC FORMS THEREOF FOR USE IN IMPROVING COGNITIVE FUNCTIONS | RED BULL GMBH (AT) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021259798-A1 | ((((3-HALOPHENYL)(PHENYL)METHYL)SULFINYL)METHYL)THIOPHENE COMPOUNDS AND DIASTEREOMERIC FORMS THEREOF FOR USE IN IMPROVING COGNITIVE FUNCTIONS | RED BULL GMBH (AT) | 2021-12-30 | — | — | WO | disclosed |
| EP-3929184-A1 | ((((3-HALOPHENYL)(PHENYL)METHYL)SULFINYL)METHYL)THIOPHENE COMPOUNDS AND DIASTEREOMERIC FORMS THEREOF FOR USE IN IMPROVING COGNITIVE FUNCTIONS | Red Bull GmbH (AT) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021048284-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES | RED BULL GMBH (AT) | 2021-03-18 | — | — | WO | disclosed |
| EP-3792252-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES. | Red Bull GmbH (AT) | 2021-03-17 | — | — | EP | disclosed |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
| WO-2003049695-A2 | COMPOUNDS TO TREAT HIV INFECTION AND AIDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1196384-A4 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1196384-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0529444-B1 | 2-Arylpropenic acids and their utilisation in the preparation of 5-ketoprofen | BAYER AG (DE) | 1997-04-16 | — | — | EP | disclosed |
| US-5362907-A | Intermediates and their use in the preparation of s-ketoprofen | BAYER AKTIENGESELLSCHAFT (DE) | 1994-11-08 | — | — | US | disclosed |
| EP-0529444-A2 | 2-Arylpropenic acids and their utilisation in the preparation of 5-ketoprofen | BAYER AG (DE) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | IDO1 3801/4885TDO2 4266/4885SMN1; SMN2 3020/4885 |
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | CHAT, PNMT, CHRM5 | IDO1 565/4885TDO2 377/4885SMN1; SMN2 483/4885 |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | IDO1 3/4885TDO2 258/4885SMN1; SMN2 4337/4885 |
| US-20220324821-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES | COMT, TST, PNMT | IDO1 1031/4885TDO2 308/4885SMN1; SMN2 1629/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | IDO1 749/4885TDO2 2970/4885SMN1; SMN2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.